



CDISC Italian User Network 2020

Milan, Italy | 7 October 2020

Efficiently Leveraging Your RWD Investment Across the Product Life Cycle

Stijn Rogiers, Pr. Industry Consultant, SAS Global Health and Life Sciences Practice



Real World Evidence

A Hot topic today...



Maximize product value beyond efficacy and safety



Equal access to healthcare
Return to work
Caregiver burden
Productivity

Society

Morbidity, Mortality
Symptoms, Functionality
Preferences, Quality of Life

Patient

Effectiveness
Tolerability
Safety
Compliance
Adherence
Convenience

Provider

Efficacy
Safety
Morbidity
Mortality

Clinical

Comparative effectiveness
Cost-utility
Budget Impact
Long-term Outcomes

Payer

Direct/Indirect Cost
Cost:Outcomes
Cost Consequences
Resource Utilization
QALY

Economic

Real-world data (RWD) and real-world evidence (RWE) are playing an increasing role in health care decisions



US FDA

1. Publication and Guidance documents incl. submission
2. Framework for FDA's RWE Program (Dec 2018)

HMA-EMA Joint Big Data Task Force

1. Publications incl. Big Data Steering Group workplan for 2020-21
2. Summary Report (Feb 2019)

National Academies of Science (US)

1. Real-World Evidence Generation and Evaluation of Therapeutics (Workshop 2017)
2. Examining the Impact of Real-World Evidence on Medical Product Development I. Incentives (Feb 2018)
3. Examining the Impact of Real-World Evidence on Medical Product Development II. Practical Approaches (Jul 2018)

The Academy of Medical Sciences (UK)

1. Real-World Evidence Generation Scoping Roundtable (Jan 2018)
2. Next steps for using real world evidence (May 2018)

RWE stream @ CDISC EU Interchanges 2019 & 2020



Big Data – Challenges and Opportunities

Moving forward with recommendations from the HMA-EMA Joint Big Data taskforce


Dr Alison Cave
Principal Scientific Administrator
Pharmacovigilance and Epidemiology Department
CDISC European Exchange May 2019



An agency of the European Union




Road to defining regulatory acceptability



CDISC Italian User Network 2020
Milan, Italy | 7 October 2020

Expanding the Use of Real-World Evidence in Regulatory and Value-Based Payment Decision-Making for Drugs and Biologics (Aug 2019)



Conclusion

Real-world evidence generated from the application of appropriate research methods and analysis of data derived from clinical, claims, and patient-facing software and systems can play a significant role in improving and modernizing both the drug evaluation and approval process and new value-based payment arrangements in the United States. Progress has already been made by the FDA in establishing a framework for the use of real-world evidence for regulatory decision-making. Significant progress has also been made by ONC and CMS in advancing interoperability and use of common standards in systems, particularly through the development of recently proposed rules. Recent efforts by HHS to promote regulatory reforms can also play a key role in modernizing evidence development.

Regulatory and payment decision-making will be informed and improved by improving regulatory clarity; increasing support for real-world evidence activities; enabling access to and analysis of data; improving its reliability and relevance; expanding pilot and demonstration projects; clearing regulatory barriers; building capacity within federal agencies; and promoting collaboration among payers, regulators, and other key stakeholders around the generation and use of real-world evidence. These steps will ultimately help to accelerate the availability of safe, effective, and affordable medicines for patients in need.

Reference: <https://bipartisanpolicy.org/report/expanding-the-use-of-realworld-evidence-in-regulatory-and-value-based-payment-decision-making-for-drugs-and-biologics/>



How to ensure that novel analytic methods are fit for decision-making (Oct 2019)

News 02/10/2019



The past decade has seen the increased generation and availability of new data sources such as real-world evidence, as well as patient-level data from completed randomised clinical trials. While these data provide an opportunity to learn more about a medicine's benefits and risks, and can complement the main body of evidence coming from randomised clinical trials, they will not necessarily translate into credible evidence for regulators and other decision-makers in the absence of adequate statistical methods to extract, analyse, and interpret them.

In an article published in *Clinical Pharmacology & Therapeutics*, regulators and academics explain how proper methodological validation can ensure the credibility of these data sources and allow authorities to rely on them to draw reliable scientific conclusions. The article is co-signed by a number of EMA staff members, academics

<https://www.ema.europa.eu/en/news/how-ensure-novel-analytic-methods-are-fit-decision-making>



Real World Evidence

PHUSE Paper (Jul 2020)



Using RWE may provide advantages in cost, cohort sizes and ethical considerations.

This PHUSE paper attempts to collate all related information such as sources of RWD (Real-World Data), privacy laws and use cases in one document which can act as a reference point for individuals or companies who wish to design, conduct, and submit studies using RWE (Real-World Evidence).

It includes FDA's current direction and guidance as of the date of this publication.

[PHUSE RWE Paper](#)



Real World Evidence

Examples



Example (Jan,2018)

J&J performed a pragmatic real-world trial, a randomized trial that used measures that are collected in clinical practice



“...INVEGA SUSTENNA® (paliperidone palmitate), a once-monthly schizophrenia treatment, is the first and only antipsychotic to have the U.S. Food and Drug Administration (FDA) approve the inclusion of real-world data in its product labeling”

<https://www.inj.com/media-center/press-releases/landmark-schizophrenia-data-that-brings-hope-in-breaking-the-cycle-of-hospitalization-and-incarceration-receives-fda-approval-for-inclusion-in-invega-sustenna-paliperidone-palmitate-label>

What's scary, and appealing, about real-world evidence (StatNews 2019)

Reference: *“Real World Evidence in Clinical development, life cycle management and/or repurposing”*
(Julijana Dukanovic, Andrew Leary – Dr. Regenold GmbH, [SAS HLS Exec Forum Basel](#), 25 June 2019)

Example (Apr,2019)

Pfizer Uses EHR Data to Support Expanded Indication for Breast Cancer Drug

“...The approval is based on RWD from electronic health records and post-marketing reports of Ibrance™ in male patients sourced from three databases: IQVIA Insurance database, Flatiron Health Breast Cancer database and the Pfizer global safety database”

The new label reads: “Based on limited data from postmarketing reports and electronic health records, the safety profile for men treated with IBRANCE is consistent with the safety profile in women treated with IBRANCE.”




<https://www.raps.org/news-and-articles/news-articles/2019/4/pfizer-uses-ehr-data-to-support-expanded-indicatio>

Reference: “Real World Evidence in Clinical development, life cycle management and/or repurposing”
(Julijana Dukanovic, Andrew Leary – Dr. Regenold GmbH, [SAS HLS Exec Forum Basel](#), 25 June 2019)



CDISC Italian User Network 2020
Milan, Italy | 7 October 2020

Stakeholders and Use Cases



- PRO
- EMR
- CLAIMS
- LABS
- RX
- REGISTRY
- COA
- SAFETY
- MORTALITY
- DIGITAL
- mHEALTH
- SOCIAL MEDIA
- CONSUMER



Synthetic Control Arms

RW02 - Addressing industry disruptions in Clinical Trials with Real World Data in lieu of COVID19

Sherrine Eid, Stijn Rogiers, Robert Collins

phuse·go-virtual

9th-13th November

EU Connect 2020

The Clinical Data
Science Conference

[Link In Post - PHUSE EU Connect 2020](#)



Real World Evidence

CDISC



CDISC RWD Connect




Figure 1: Major Activities and Sources of Real World Data

<https://www.cdisc.org/standards/real-world-data>



CDISC Italian User Network 2020
Milan, Italy | 7 October 2020

Call for Abstracts (incl. RWE stream)

CDISC EU Interchange 2021

Stijn Rogiers

E3C Member and Principal Industry Consultant, Global Health and Life Sciences Practice, SAS



Earlier this year we made a drastic decision and changed the EU CDISC Interchange 2020 from an in-person (Berlin) conference to a virtual event in a matter of weeks/days.

It was a real challenge, but we did it! What a great CDISC E3C/ CDISC team effort, considering the short deadline we faced. **You can only do this when you are well-prepared and act as ONE team.**

Approximately six months later, the E3C team met virtually for two half days (10-11 Sep) to start planning the **EU interchange 2021**.

As COVID-19 will continue to impact our lives for a while, the logical decision was made by CDISC and the CDISC E3C team to start preparing for another **virtual event** (*most probably last week of April 2021*).

CDISC E3C “**Godfather**” **Joerg Dillert** kept an eye on the Virtual E3C meeting and noticed that the preparation with new lead **Nick De Donder** and co-lead **Sujit Khune** ran very smoothly.

Meeting topics included feedback from this year CDISC 2020 Europe Virtual Interchange, new ideas and trends for the upcoming event, the new virtual platform and its capabilities, **COVID-19**, **CDISC-360**, keynote presentations), CDISC (virtual) trainings, the collaboration with CDISC (country) teams and many more.

- The **call for abstracts will open 9 Oct 2020**. Check out the CDISC website and follow **CDISC** and E3C team members on social media to get all latest updates on this upcoming event.
- Final **submission deadline is set for 8 Jan 2021**. We encourage you to share your expertise by submitting an abstract. Don't forget... **Sharing Is Caring!**

Are you interested in joining the CDISC E3C team ?

We are always looking for enthusiastic industry talents from Pharma, CRO, Academia,

Technology, or Regulatory to strengthen our diverse team.

Stay tuned for an official CDISC announcement soon.

Don't hesitate to **contact us** in the meantime.

[Linked In Post](#)

[cdisc eu interchange 2021 \(E3C article\)](#)



CDISC Italian User Network 2020
Milan, Italy | 7 October 2020

Real World Evidence

How does SAS support our customers ?



Overcome challenges



BIAS



FIT FOR PURPOSE
DATA



TRANSPARENCY



GOVERNANCE



REPRODUCIBILITY

DATA STANDARDIZATION



SAS® Health



Data
Management



Exploratory
Analyses



Accelerated
Analytics and
Reporting



SAS® Health

SAS® Health Solutions

SAS® Life Science Analytics Framework
SAS® Cohort Builder
SAS® Episode Builder
SAS® Data Mapper
SAS® Visual Investigator

SAS® Health Analytic Insight Modules - AIMs

Payer
Provider
Public Health
Life Sciences

(App Store)



SAS® Analytics

Manage the complete Analytical Life Cycle
for Continuous Innovation

https://www.sas.com/en_us/software/health.html



SAS® Health – Managing your Data Sources



SAS® Health - Build Cohorts

Data Sources Projects

Filter

CMS50K
Date modified: Feb 7, 2020
Completed

HAF50K
Date modified: Nov 5, 2019
Completed

1K HCI3 ICD9
Date modified: Feb 7, 2020
Completed

HCI50K
Date modified: Feb 7, 2020
Completed

CMS1K
Date modified: Feb 7, 2020
Completed

1K CMS ICD9
Date modified: Feb 10, 2020
Error

1K CMS ICD9 test2
Date modified: Feb 10, 2020
Error

try800k
Date modified: Dec 17, 2019
Completed

Select one item to see its information.

Summary Profile Framework Menu

Name: CMS50K

Description:

Registered: ✔

Date modified: Feb 7, 2020

Modified by: jomsan

Date created: Feb 7, 2020

Created by: jomsan

Member count: 50000

Enrollment: ✔

Observation: ✘

Prescription: ✔

Claims: ✔

CASLib Path: /sea/warehouse/9_HAF44_SEA/cf03d6a2-63b...

Data source ID: 3074446b896...

SAS® Health – Data Sources insights



Data sources	CMS50K	HAF50K	try800k
Member count	50000	50000	843524
Enrollment	✓	✓	✓
Observation	✗	✓	✗
Prescription	✓	✓	✓
Claims	✓	✓	✓
Distribution Metrics			
Distribution By Gender			
Distribution By Ethnicity			
Distribution By Race			
Distribution By Age Group			

[Administration](#)

Cohorts

[Analysis Variables](#)

[Expression Manager](#)

SAS Resources

[SAS Health](#)

SAS® Health – Collaboration across departments and user Profiles



Filter

Summary Details Framework Menu

NewProject
Type: Cohort
Happy New Year
Owner: limakk
Last modified: 4 weeks ago

priya1
Type: Cohort
test1
Owner: prthir
Last modified: 3 weeks ago

arkada122
Type: Cohort
testing sasdrive
Owner: arkada
Last modified: 2 weeks ago

H
Type: Cohort
Owner: hebinn
Last modified: 2 weeks ago

Don N
Type: Cohort
Owner: donash
Last modified: 12 days ago

projectel
Type: Cohort
Owner: erlync
Last modified: 11 days ago

Project0130

novarg_project01

Project0203

Population Cohorts:
[AVCohort](#)
[Population 0121.1](#)
[UXTest Cohort](#)
[Cohort2020](#)
[A New Test 1](#)
[UX Cohort](#)
[Test](#)

Index Event Cohorts:
none

SAS® Health – Building Cohorts in minutes/hours instead of days/weeks



SAS® Health - Build Cohorts

HOME > PROJECT
Expression Builder

Name: TestIndexCohort
Data source: CMS50K n=50,000
Cohort Count: n=2,004

Build Analyze Explore

Concepts Index Events Saved Concepts

Search for codes

- Demographics
- Diagnoses - Dx
- Diagnosis Related Groups
- Prescriptions - Rx
- Procedures - Px
- Visits

Index Event: Type 2 Diabetes

AND OR NOT

Age at Index Date >= 18 n = 28751

Gender Code Female n = 16646

Diagnoses - Asthma n = 2004

Attrition Proportion



Age at Index n=28,751 100%

Gender Code n=16,646 58%



Diagnoses - n=2,004 7%

The screenshot displays the SAS Health Expression Builder interface. At the top, there's a navigation bar with "HOME > PROJECT" and "Expression Builder". A progress bar shows "Build" (active), "Analyze", and "Explore". On the right, it shows "Name: TestIndexCohort", "Data source: CMS50K n=50,000", and "Cohort Count: n=2,004". The main area is divided into three sections: a left sidebar with a search bar and a tree view of categories (Demographics, Diagnoses - Dx, etc.); a central workspace for building the cohort expression, currently showing "Index Event: Type 2 Diabetes" with filters for "Age at Index Date >= 18", "Gender Code Female", and "Diagnoses - Asthma"; and a right sidebar showing a summary of the cohort's characteristics with horizontal bar charts for "Age at Index" (100%), "Gender Code" (58%), and "Diagnoses -" (7%).

SAS® Health – Analysis on Cohorts of interest



SAS® Health – Analysis on Cohorts of interest



SAS® Health – Meet Regulatory Requirements

Submit Code and Logs



The screenshot displays the SAS Studio interface. On the left, the 'Tasks' pane shows a tree view of machine learning tasks, with 'Gradient Boosting' selected under 'Supervised Learning'. The main workspace is divided into three panes: 'DATA', 'ROLES', and 'Code Log'. The 'DATA' pane shows the dataset 'PUBLIC.SYNTHEA_100K_NTP...' and 'Partition Data' options. The 'ROLES' pane shows 'Target' set to 'Use a nominal target'. The 'Code Log' pane shows the SAS code for a gradient boost procedure.

```
1 /*
2 *
3 * Task code generated by SAS® Studio 5.2
4 *
5 * Generated on '9/4/20, 4:18 PM'
6 * Generated by 'robcol'
7 * Generated on server 'CPOC-Viya-Services'
8 * Generated on SAS platform 'Linux LIN X64 3.10.0-957.5.1.e
9 * Generated on SAS version 'V.03.05M0P11112019'
10 * Generated on browser 'Mozilla/5.0 (Windows NT 10.0; Win64
11 * Generated on web client 'https://sashlab.eastus.cloudap
12 */
13
14 ods noproctitle;
15
16 proc gradboost data=PUBLIC.SYNTHEA_100K_NTPROBNP;
17     target VALUE_N / level=nominal;
18     input DATE / level=interval;
19 run;
```

SAS® Health – OPEN platform

The screenshot shows the SAS Developer Home website. The header includes navigation links for Home, SAS Tools, Developer GitHub Resources, and SAS Communities. The main content area features a large banner with the text "SAS Developer Home" and "Resources for developers on SAS and open source". Below the banner, there are sections for "What's New?", "Developers Community", "SAS on GitHub", and "SAS Tools". The bottom section is titled "Explore APIs and Development Resources" and includes filters for solution, role, and technology. It displays several resource cards for "Open Source SAS", "REST", and "Python".

The screenshot shows the SAS Software GitHub profile page. The header includes navigation links for Why GitHub?, Team, Enterprise, Explore, Marketplace, Pricing, Search, Sign in, and Sign up. The main content area features a banner with the text "Grow your team on GitHub" and "GitHub is home to over 50 million developers working together. Join them to grow your own development teams, manage permissions, and collaborate on projects." Below the banner, there are sections for "Pinned repositories" and "Repositories". The pinned repositories section displays several repository cards, including "covid-19-sas", "python-dlpy", "sas-container-recipes", "saspy", "sas-prog-for-r-users", and "python-swat".



[Developer.SAS.com](https://developer.sas.com) and [SAS on GitHub](https://github.com/SAS)



Any Questions ?

stijn.rogiers@sas.com

<https://www.linkedin.com/in/stijnrogiers/>
[Twitter @StijnRogiers](#)

sas.com





Thank you !

sas.com

